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Abstract
Purpose Pegylated granulocyte-colony-stimulating factor (G-
CSF) is frequently used to prevent febrile neutropenia (FN) in
patients undergoing chemotherapy with a high risk of
myelosuppression. This phase II/III study was conducted to
determine the adequate dose of pegteograstim, a new formu-
lation of pegylated G-CSF, and to evaluate the efficacy and
safety of pegteograstim compared to pegfilgrastim.
Methods In the phase II part, 60 breast cancer patients who
were undergoing DA (docetaxel and doxorubicin) or TAC
(docetaxel, doxorubicin, and cyclophosphamide) chemother-
apy were randomly selected to receive a single subcutaneous
injection of 3.6 or 6.0 mg pegteograstim on day 2 of each
chemotherapy cycle. The phase III part was seamlessly started
to compare the dose of pegteograstim at selected in phase II
with 6.0 mg pegfilgrastim in 117 breast cancer patients. The
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primary endpoint of both the phase II and III parts was the
duration of grade 4 neutropenia in the chemotherapy cycle 1.
Results The mean duration of grade 4 neutropenia for the
3.6 mg pegteograstim (n = 33) was similar to that for the
6.0 mg pegteograstim (n = 26) (1.97 ± 1.79 days vs.
1.54 ± 0.95 days, p = 0.33). The 6.0 mg pegteograstim was
selected to be compared with the 6.0 mg pegfilgrastim in the
phase III part. In the phase III part, the primary analysis re-
vealed that the efficacy of pegteograstim (n = 56) was non-
inferior to that of pegfilgrastim (n = 59) [duration of grade 4
neutropenia, 1.64 ± 1.18 days vs. 1.80 ± 1.05 days; difference,
−0.15 ± 1.11 (p = 0.36, 97.5% confidence intervals = 0.57 and
0.26)]. The time to the absolute neutrophil count (ANC) re-
covery of pegteograstim (≥2000/μL) was significantly shorter
than that of pegfi lgrast im (8.85 ± 1.45 days vs.
9.83 ± 1.20 days, p < 0.0001). Other secondary endpoints
showed no significant difference between the two groups.
The safety profiles of the two groups did not differ
significantly.
Conclusions Pegteograstim was shown to be as effective as
pegfilgrastim in the reduction of chemotherapy-induced neu-
tropenia in the breast cancer patients who were undergoing
chemotherapy with a high risk of myelosuppression.
Keywords Chemotherapy-induced neutropenia . Breast
cancer . PegylatedG-CSF . Pegteograstim . Prophylaxis
Introduction
Myelosuppression is the most common form of dose-limiting
toxicity of conventional anticancer chemotherapies, which re-
stricts their application. Chemotherapy-induced febrile neu-
tropenia (FN) is especially life threatening in some patients,
requiring hospitalization, intravenous (IV) antibiotic therapy,
and dose reduction in subsequent cycles, which compromise
the efficacy of chemotherapy. Thus, recent guidelines recom-
mend primary or secondary prophylaxis with granulocyte-
colony-stimulating factors (G-CSFs) before using FN high-
risk chemotherapy regimens or before subsequent cycles after
the development of FN in the previous cycle [1].
Whereas filgrastim has a plasma half-life of 110 min
and requires daily injection [2], pegfilgrastim (Neulasta®,
Amgen, Thousand Oaks, CA, USA), a pegylated form of
filgrastim, has an increased half-life (about 33.2 h) and
duration of action (about 8.3 days) [3, 4]. Generally,
pegfilgrastim is administered monthly, and conventional
G-CSF is dosed daily, which implies the comparable effi-
cacy of pegfilgrastim with improved convenience and
safety [5, 6]. Several studies showed that pegfilgrastim
is associated with a lower risk of hospitalization of cancer
patients than filgrastim and cost-effective. [7–9].
Pegteograstim is a novel recombinant human G-CSF con-
jugated with methoxy-maleimide-polyethylene glycol, which
was developed by Green Cross Corporation in Korea. As it
bears a PEG anchored to a unique site in the structurally flex-
ible CD-loop region of G-CSF, which is located far from re-
ceptor binding sites, it has higher affinity to the G-CSF recep-
tor and correspondingly higher in vitro biological activity than
pegfilgrastim (data not shown).
In the previous phase I study, the PK-PD characteristics of
30–100 μg/kg of pegteograstim were comparable to those of
100 μg/kg of pegfilgrastim, and 100 μg/kg of pegteograstim
showed a 20 % greater increase in their absolute neutrophil
count (ANC) and CD34+ cell counts than pegfilgrastim.
Furthermore, 30–100 μg/kg of pegteograstim was well toler-
ated in healthy Korean males [10].
Based on the phase I study, we conducted a multicenter,
randomized, seamless phase II/III study to demonstrate the
non-inferiority of pegteograstim to pegfilgrastim in breast can-
cer patients, in terms of the duration of grade 4 neutropenia
(ANC < 500/μL) during the first chemotherapy cycle. Before
proceeding to the phase III part, we explored the optimal dose




Female patients were eligible for inclusion in this study if
they had breast cancer and planned to undergo DA
(75 mg/m2 docetaxel plus 50 mg/m2 doxorubicin on day
1 every 3 weeks) chemotherapy or TAC (75 mg/m2 doce-
taxel plus 50 mg/m2 doxorubicin plus 500 mg/m2 cyclo-
phosphamide on day 1 every 3 weeks) chemotherapy. The
other eligibility criteria included an age of at least
18 years, body weight ≥45 kg, Eastern Cooperative
Oncology Group (ECOG) performance status ≤2, ANC
≥1500/μL, platelet count ≥100000/μL, and life expectan-
cy ≥3 months. The exclusion criteria were exposure to
antibiotics within 72 h before the chemotherapy; moderate
to severe heart failure according to the New York Heart
Association functional classification III–IV or clinically
significant cardiac dysfunction; a history of bone marrow
or stem cell transplantation; exposure to pegfilgrastim,
filgrastim, sargramostim (GM-CSF), or lenograstim with-
in 4 weeks of the patient’s consent to participate in this
study; pregnancy or breast feeding female patients; cysti-
tis or urinary outlet obstruction; and major surgery unre-
lated to anticancer treatment within 4 weeks of the patient
registration. All the female patients provided their written
informed consent to participate in this study.
1710 Support Care Cancer (2016) 24:1709–1717
Study design
This study is a randomized, multicenter, seamless phase II
(single-blinded)/III (double-blinded) study (Fig. 1). In the
phase II part, the female patients were randomized (1:1) to
receive either a subcutaneous injection of 3.6 or 6.0 mg
pegteograstim in a single-blinded manner on day 2 of each
chemotherapy cycle. Although up to four cycles of chemo-
therapy were planned, up to six cycles of additional treatments
were allowed at the discretion of the investigators. In addition,
follow-up was conducted 12 weeks after the completion of the
study treatment to determine the anti-drug antibody formation.
The phase III part was designed to test the non-inferiority of
pegteograstim to pegfilgrastim. The female patients were ran-
domized at 1:1 in a double-blinded manner to receive either
the study drug (6.0 mg pegteograstim, the dose selected in
phase II) or the comparator (6.0 mg pegfilgrastim). The ran-
domization was stratified according to the type of chemother-
apy (DA versus TAC), and the patients received the study
medication on day 2 of each chemotherapy cycle, for up to
six cycles.
This study was conducted in full accordance with the
guidelines for Good Clinical Practice and the Declaration of
Helsinki. The Korean Cancer Study Group (KCSG) Protocol
Review Committee approved the study protocol, and the ap-
proval of the Institutional Ethics Committees was obtained
before the start of the patient accrual at each institution. This
trial has been registered at ClinicalTrials.gov as
NCT01328938.
Phase II
The female patients were intravenously administered four to
six cycles of DA or TAC chemotherapy. They were randomly
assigned to group I (3.6 mg) or group II (6.0 mg) with strati-
fication by institution and type of chemotherapy (DA vs.
TAC). Each female patient received a single subcutaneous
injection of pegteograstim at either dose on day 2 (24 h after
the chemotherapy) of each cycle in a single-blinded manner.
After the optimal or appropriate dose of pegteograstim was
selected, the study seamlessly proceeded to phase III.
Phase III
The female patients were administered the same chemothera-
py regimen and schedules as in phase II but received the dose
of pegteograstim at selected in phase II or the comparator
(6.0 mg of pegfilgrastim) in a double-blinded manner. The
patients who required therapeutic G-CSF administration at
the discretion of the investigators were excluded from the
efficacy analyses. Prophylactic antibiotic therapy was not
allowed during cycle 1, but allowed from cycle 2, based on
the judgment of the investigators for those who suffered per-
sistent (>7 days) grade 4 neutropenia in cycle 1.
Corticosteroid use was prohibited, except for anti-emetic
purposes.
Outcome measurements
The primary endpoint in both the phase II and III parts was the
duration (in days) of grade 4 neutropenia during the first che-
motherapy cycle in both phases. Grade 4 neutropenia was
defined as ANC <500/μL. The secondary endpoints in phase
II were the time (in days) to the recovery to ANC ≥2000/μL
after the nadir during cycle 1, the incidence of FN, the safety
profile, and the formation of an anti-drug antibody against the
administered study drug. FN was defined as a condition with
an ANC <500/μL, and fever, as a condition with a single oral
temperature of ≥38.3 °C or two or more instances of ≥38.0 °C
each taken within 1–24 h after the initial measurement. In
phase III, the secondary endpoints were the time (in days) to
the recovery to ANC ≥2000/μL after the ANC nadir during
cycle 1, the incidence of FN, the ANC nadir during cycle 1,
the incidence of persistent grade 4 neutropenia over 3 days or
longer, the ANC value on day 7 during all the chemotherapy
cycles, the number of days of hospitalization due to FN after
cycle 2, the number of cases of IVantimicrobial usage due to
FN, and incidence of delay or dose reduction of
chemotherapy.
Statistical analyses
To determine the optimal dose of pegteograstim between 3.6
and 6.0 mg at the one-sided α level of 0.1 and the power of
Fig. 1 Overall scheme of study
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80%, phase II required 30 patients in each group. In phase III,
we estimated the need for 60 patients in each group to dem-
onstrate the non-inferiority of pegteograstim to pegfilgrastim
at the one-sided α level of 0.025 and the power of 90 %. Non-
inferiority was concluded if the upper limit of the 97.5 % one-
sided confidence interval of the inter-group difference in the
duration of grade 4 neutropenia did not exceed the limit of 1.0,
which was in accordance with the non-inferiority margin.
The primary endpoint was analyzed using the modified
intention-to-treat (ITT) set, which is defined as the patients
who received the study drug at least once and were evaluable
for the efficacy after the first cycle. Safety analyses were con-
ducted in the safety analysis (SA) set, which included any
subject who received the study drug at least once.
Results
Patients
Between October 2010 and January 2012, 60 female patients
were enrolled in the phase II part of this study (Table 1).
Thirty-four patients were randomized to the 3.6 mg
pegteograstim group, and 26, to the 6.0 mg group. Two pa-
tients in the 3.6 mg group were withdrawnwithout completing
cycle 1 due to their inadequate baseline ANC (ANC <1500/
μL). Following the analysis to determine the optimal dose of
pegteograstim after phase II, 117 female patients were recruit-
ed from February 2012 to May 2013 for the phase III part
(Fig. 2). Fifty-eight patients were randomized to the
pegteograstim group, and 59, to the pegfilgrastim group.
One patient in the pegteograstim group who did not receive
the study drug due to violation of the inclusion criteria was
excluded from the safety analyses. One patient randomized to
the pegteograstim group received the study drug but was ex-
cluded from the analyses because she underwent the G-CSF
treatment during FN in cycle 1, and 115 female patients (56 in
the pegteograstim group and 59 in the pegfilgrastim group)
were assessed for efficacy. The mean age of the subjects in
both groups was 49 years.
Overall, 18.2 % (32/176) of the patients had previously
undergone chemotherapy, and 13.1 % (23/176) had under-
gone adjuvant radiotherapy, with no imbalance between the
groups. Of the patients, 73.3 % (129/176) underwent
adjuvant/neoadjuvant chemotherapy as the study protocol reg-
imen and 26.7 % (47/176) underwent first-line palliative che-
motherapy as the study protocol regimen, without imbalance
between the groups. Sub-analysis was conducted to compare
the FN incidence by the treatment intents, palliative vs. adju-
vant/neoadjuvant. FN rates of palliative treatment were higher
Table 1 Demographic and baseline characteristics










No % No % No % No %
Age 0.24 0.66
Median 47.5 47 49 49
Range 31–73 29–72 32–74 28–72
Previous chemotherapy 0.15 0.62
Yes 12 35 6 23 6 10.5 8 13.6
No 22 65 20 77 51 89.5 51 86.4
Previous radiotherapy 0.48 0.49
Yes 8 23.5 6 23.1 3 5.3 6 10.2
No 26 76.5 20 76.9 54 94.7 53 89.8
ECOG 0.18 0.26
0 22 64.7 12 46.2 33 57.9 38 64.4
1 11 32.4 13 50.0 24 42.1 19 32.2
2 1 2.9 1 3.8 0 0.0 2 3.4
Chemotherapy regimen 0.45 0.87
DA 23 67.6 18 69.2 25 43.9 25 42.4
TAC 11 32.4 8 30.8 32 56.1 34 57.6
Aim of chemotherapy 0.33 0.73
Adjuvant/neoadjuvant 21 61.8 18 69.2 45 78.9 45 76.3
Palliative 13 39.2 8 30.8 12 21.1 14 23.7
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than those of adjuvant/neoadjuvant for both studies, but not
significantly so. In both study parts, two groups also had bal-
anced chemotherapy regimens and disease status at the base-
line. Twenty-seven of thirty-four patients (79.4 %) in the
3.6 mg group and 23/26 patients (88.5 %) in the 6.0 mg group
completed all the six chemotherapy cycles in the phase II part.
Forty-seven of fifty-eight patients (81.0 %) in the study group
and 46/59 patients (78.0 %) in the control group completed all
the six chemotherapy cycles in the phase III part.
Phase II
There was no significant difference in the mean duration of
grade 4 neutropenia (±SD) between group I (3.6 mg) and
group II (6.0 mg): 1.97 ± 1.79 days and 1.54 ± 0.95 days,
respectively (p = 0.33). The median was 2 days in both
groups. The times to recovery to ANC ≥2000/μL after the
ANC nadir were 10.33 ± 2.68 days in the 3.6 mg group and
9.69 ± 1.87 days in the 6.0 mg group (p = 0.16). The incidence
rates of FN in each group were 3 and 2, respectively (9.1 vs.
7.7 %, p = 0.74), and the ANC nadir values (258.2/μL and
213.6/μL, p = 0.13) also showed no significant difference
between the two groups (Table 2). The common adverse
events (AEs) were nausea, myalgia, and peripheral neuropa-
thy.Most of these AEs hadmild to moderate severity and were
considered related to the chemotherapy, and there was no dif-
ference in the incidence of AEs between the two groups (data
not shown). The development of an anti-drug antibody was
not observed in both groups. Although there was no
significant difference in the primary and secondary endpoints,
the Steering Committee selected 6.0 mg as the recommended
dose for proceeding to phase III because there was no dose-




In the ITT population, the mean (±SD) duration of grade 4 neu-
tropenia was comparable in both treatment groups:
1.80 ± 1.05 days in the pegfilgrastim group and 1.64 ± 1.18 days
in the pegteograstim group. The 97.5 % confidence interval for
the mean difference was (−0.57 and 0.26). As a result, the study
met the non-inferiority criterion. Among the secondary efficacy
endpoints, the time (in days) to recovery to ANC ≥2000/μL in
the pegteograstim group was 8.85 ± 1.45 days, which was sig-
nificantly shorter than the 9.83 ± 1.20 days in the pegfilgrastim
group (p < 0.0001) (Fig. 3). The incidence of FN did not differ
between the two groups. Eleven subjects (19.6 %) in the
pegteograstim group and nine (15.3 %) in the pegfilgrastim
group developed FN (p = 0.53). Five patients in the
pegteograstim group and three in the pegfilgrastim group were
hospitalized due to FN (p = 0.49), and 11 patients in the
pegteograstim group and nine in the pegfilgrastim group
underwent antibiotic therapy (p = 0.53).
With regard to the other secondary endpoints, the numeric
differences favored pegteograstim over pegfilgrastim,
Fig. 2 Disposition of patients in
the trial
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although they were not statistically significant. The incidences
of persistent grade 4 neutropenia over 3 days were 8 (14.6 %)
in the pegteograstim group and 13 (22.4 %) in the
pegfilgrastim group (p = 0.28). The numbers of cases in which
a delay or dose reduction in chemotherapy was required were
12 (23.1 %) and 22 (37.9 %) in the pegteograstim and
pegfilgrastim groups, respectively (p = 0.09). The depths of
neutropenia (the ANC nadirs) in cycle 1 were 290.4 ± 362.0/
μL in the pegteograstim group and 198.3 ± 199.7/μL in the
pegfilgrastim group (p = 0.09). The ANC counts on day 7 of
cycle 1 were 1064.1 ± 1098.7 and 918.8 ± 869.3 (p = 0.32).
The subgroup analyses according to the type of chemo-
therapy (DA vs. TAC). In the chemotherapy with 6.0 mg
pegteograstim, there was no significant difference in the
mean duration of grade 4 neutropenia (±SD) between the
TAC regimen and the DA regimen: 1.84 ± 1.21 days and
1.4 ± 1.15 days, respectively (p = 0.26). In the chemo-
therapy with 6.0 mg pegfilgrastim, there was no signifi-
cant difference in the mean duration of grade 4 neutrope-
nia (±SD) between the TAC regimen and the DA regimen:
1.96 ± 0.93 days and 1.68 ± 1.12 days, respectively
(p = 0.31).
Table 2 Efficacy evaluation in phase II and phase III












(N = 33) (N = 26) (N = 56) (N = 59)
Duration (days) of grade 4 neutropenia 1.97 ± 1.79 1.54 ± 0.95 0.33 1.64 ± 1.18 1.80 ± 1.05 −0.15 ± 1.11a
[−0.57, 0.26]
ANC recovery time (days)a 10.33 ± 2.68 9.69 ± 1.87 0.16 8.85 ± 1.45 9.83 ± 1.20 <0.0001
Incidence of FN (N, %)b 3 (9.1) 2 (7.7) 0.74 11 (19.6) 9 (15.3) 0.53
ANC nadirc 258.2 ± 249.9 213.6 ± 240.4 0.13 290.4 ± 362.0 198.3 ± 199.7 0.09
ANC on day 7d NA NA NA 1064.1 ± 1098.7 918.8 ± 869.3 0.32
Incidence of persistent grade 4 neutropenia over
3 days or longere
NA NA NA 8 (14.6) 13 (22.4) 0.28
Incidence of delay or dose reduction in
chemotherapyf
NA NA NA 12 (23.1) 22 (37.9) 0.09
NA not available
a Time (days) to recovery to ANC ≥2000/mm3 following ANC nadir during cycle 1
b Frequency and percentage of patient with at least one febrile neutropenia during each cycle
c ANC nadir during cycle 1
dMean ANC value on day 7 at each cycle
e Frequency and percentage of patient with persistent grade 4 neutropenia over 3 days or longer during cycle 1
f Frequency and percentage of patient with at least one delay or dose reduction in chemotherapy due to neutropenia at each cycle
Fig. 3 Changes in mean absolute
neutrophil count (ANC)
chemotherapy cycle 1 (phase III
part)
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Also, the history of chemotherapy or radiotherapy, or the
treatment setting (adjuvant/neoadjuvant vs. palliative) showed
no significant difference in the primary or secondary out-
comes between the pegteograstim and pegfilgrastim groups
(data not shown).
Safety
AEs occurred in 55 patients (96.5 %) in the pegteograstim
group and in 59 patients (100 %) in the pegfilgrastim group.
The frequent AEs were nausea, myalgia, constipation, periph-
eral neuropathy, and decreased appetite, most of which were
due to the chemotherapy, especially the docetaxel chemothera-
py (Table 3). Adverse drug reactions (ADRs), wherein the caus-
al relationship between the AEs and the study drugs could not
be excluded, were 5.3 and 3.4 % in the pegteograstim group
and the pegfilgrastim group, respectively. The ADRs were leu-
kocytosis, blurred vision, injection site pain, pyrexia, dizziness,
headache, and peripheral sensory neuropathy. One out of 116
patients showed leukocytosis (≥30,000/μL). The marked leu-
kocytosis (75,000/μL) was observed from day 2 of cycle 5 to
day 1 of cycle 6 in the pegteograstim group and was resolved
without any complication. There was no significant difference
in the incidence of AEs or ADRs between the groups.
Discussion
The results of this phase II/III study demonstrated the non-
inferiority of pegteograstim to pegfilgrastim in the prevention
of severe neutropenia after high-risk chemotherapy in breast
cancer patients. The duration of grade 4 neutropenia and the
incidence of FN in the patients who received prophylactic
pegteograstim were comparable to those in the patients who
received pegfilgrastim. The duration of grade 4 neutropenia
observed in phase III (1.64 days) substantiates the result in
phase II of 1.54 days for the 6.0 mg group. The median dura-
tion of grade 4 neutropenia in the patients who underwent
docetaxel plus doxorubicin chemotherapy but were not treated
with G-CSF has been reported to range from 4 to 7 days
[11–13]. Based on the results of this study, both pegteograstim
and pegfilgrastim are expected to reduce the duration of grade
4 neutropenia by more than half. Primary prophylaxis with
CSF is known to reduce the risks of hospitalization and all-
cause mortality in breast cancer patients undergoing chemo-
therapy [14]. Therefore, pegteograstim is expected to have a
clinically relevant effect on the prevention of FN and on the
safety of breast cancer patients undergoing myelosuppressive
chemotherapy.
In the phase II part of this study, there was no significant
difference between the 3.6 and 6.0 mg pegteograstim groups in
terms of the duration of grade 4 neutropenia and the other
secondary endpoints. However, in the previously reported
phase I study of pegteograstim in healthy subjects, the higher
doses (100 and 300 μg/kg) showed higher-level activity in
terms of the maximum ANC and CD34+ cell counts as well
as superior pharmacokinetic parameters [10]. In addition, no
dose-dependent increase in AEs or ADRs was observed in
phase II of this study. Therefore, the high dose (6.0 mg) tested
in this study was considered within the maximum dose range
for safe use and was selected as the dose for the study group in
phase III.
Among the secondary efficacy endpoints, the time to recovery
to ANC ≥2000/μL in the pegteograstim group was significantly
shortened by 1 day comparedwith that in the pegfilgrastim group
(8.85 vs. 9.83 days, p < 0.0001). In the previously reported phase
I study, a more significantly increased activity of pegteograstim
on ANC and CD34+ cells than with the same dose of
pegfilgrastim was suggested [10]. The study showed that al-
though pegteograstim has 19 % lower systemic exposure than
pegfilgrastim at the same dose, it is associatedwith a 20% higher
area under the effect-time curve (AUEC) values for the plasma
ANC and CD34+ cell counts. The lower systemic exposure with
the higher activity of pegteograstim is explained by its more
prominent target-mediated drug disposition (TMDD) pattern of
elimination than that of pegfilgrastim. Much of pegteograstim is
eliminated by receptors on neutrophil or CD34+ cells, and in-
creased clearance indicates increased activity on ANC and
CD34+ cells (i.e., increased receptors).
Although there was no difference between the groups, the
incidences of FN in this study (19.6 % in the pegteograstim
group and 15.3 % in the pegfilgrastim group) were somewhat
higher than those in other studies that reported the incidence of
FN as less than 10 % using prophylactic G-CSF [15–19].
However, since the incidences of FN greatly vary according
to the differences in the definition of FN, the chemotherapy
regimens and duration of treatment, the primary prophylaxis
with antibiotics, and the eligibility for prior chemotherapies,
the inter-trial comparison should be conducted with care. In
this study, the definition of FN is less restrictive (≥38.3 °C
measured once or two or more instances of ≥38.0 °C each
taken within 1–24 h after the initial measurement), and more
than 10 % of the patients had chemotherapy treatment before
their inclusion in this study.
The limitations of this study were the small number of
patients and the defined treatment regimen in the study popu-
lation. However, similar to pegfilgrastim, pegteograstim
showed a favorable safety profile. Its frequent AEs were my-
algia, peripheral neuropathy, decreased appetite, nausea, and
constipation, most of which are known to be associated with
chemotherapy. Based on this study, further clinical trials are
being conducted and planned. A post-marketing surveillance
study is now being performed to assess the further safety pro-
file of pegteograstim, and additional trials with various cancer
types, patient populations, and treatment regimens are
warranted.
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Conclusion
This study showed that 6.0 mg pegteograstim is as effective as
6.0 mg pegfilgrastim in reducing the risk of chemotherapy-
induced neutropenia with a tolerable safety profile.
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All grade Grade 3/4 All grade Grade 3/4 All grade Grade 3/4 All grade Grade 3/4
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Open Access This article is distributed under the terms of the Creative
Commons Attribution-NonCommercial 4.0 International License
(http://creativecommons.org/licenses/by-nc/4.0/), which permits any
noncommercial use, distribution, and reproduction in any medium,
provided you give appropriate credit to the original author(s) and the
source, provide a link to the Creative Commons license, and indicate
if changes were made.
1716 Support Care Cancer (2016) 24:1709–1717
11. Misset JL, Dieras V, Gruia G, Bourgeois H, Cvitkovic E, Kalla S,
et al. (1999) Dose-finding study of docetaxel and doxorubicin in the
first-line treatment of patients with metastatic breast cancer. Ann
Oncol 10(5):553–560
12. Nabholtz JM, Falkson C, Campos D, Szanto J, Martin M, Chan S,
et al. (2003) TAX 306 Study Group. Docetaxel and doxorubicin
compared with doxorubicin and cyclophosphamide as first-line
chemotherapy for metastatic breast cancer: results of a randomized,
multicenter, phase III trial. J Clin Oncol. Mar. 15; 21 (6): 968–75.
Erratum in:. J Clin Oncol 21(10):2048
13. del Giglio A, Eniu A, Ganea-Motan D, Topuzov E, Lubenau H (2008)
XM02 is superior to a placebo and equivalent to Neupogen in reducing
the duration of severe neutropenia and the incidence of febrile neutro-
penia in cycle 1 in breast cancer patients receiving docetaxel/
doxorubicin chemotherapy. BMC Cancer 8:332
14. Renner P, Milazzo S, Liu JP, Zwahlen M, Birkmann J, Horneber M
(2012) Primary prophylactic colony-stimulating factors for the pre-
vention of chemotherapy-induced febrile neutropenia in breast can-
cer patients. Cochrane Database Syst Rev 10:CD007913
15. Kosaka Y, Rai Y, Masuda N, Takano T, Saeki T, Nakamura S, et al.
(2015) Phase III placebo-controlled, double-blind, randomized trial
of pegfilgrastim to reduce the risk of febrile neutropenia in breast
cancer patients receiving docetaxel/cyclophosphamide chemother-
apy. Support Care Cancer 4:1137–1143
16. Bondarenko I, Gladkov OA, Elsaesser R, Buchner A, Bias P (2013)
Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a ran-
domized, multicenter, active-control phase 3 trial in patients with
breast cancer receiving doxorubicin/docetaxel chemotherapy. BMC
Cancer 13:386
17. MartínM, Lluch A, Seguí MA, Ruiz A, RamosM, Adrover E, et al.
(2006) Toxicity- and health-related quality of life of breast cancer
patients receiving adjuvant docetaxel, doxorubicin, and cyclophos-
phamide (TAC) or 5-fluorouracil, doxorubicin, and cyclophospha-
mide (FAC): impact of adding a primary prophylactic granulocyte-
colony-stimulating factor to the TAC regimen. Ann Oncol 17(8):
1205–1212
18. Aapro MS et al. (2011) 2010 update of EORTC guidelines for the
use of granulocyte colony stimulating factor to reduce the incidence
of chemotherapy-induced febrile neutropenia in adult patients with
lymphoproliferative disorders and solid tumours. Eur J Cancer 47:
8–32
19. vonMinckwitz G, Kümmel S, du Bois A, et al (2008) Pegfilgrastim
± ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxo-
rubicin/cyclophosphamide) chemotherapy for breast cancer.
Results from the GEPARTRIO Study Annals of Oncology 19:
292–298
Support Care Cancer (2016) 24:1709–1717 1717
